In Section A, participants will obtain different doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. More participants will likely be enrolled on the determined monotherapy dosign program. In Segment B, members will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase C, https://isabbv-744effectiveforhem92467.myparisblog.com/32554060/clinical-trial-recruitment-for-abbv-744-study-fundamentals-explained